Gossamer Bio, Inc.NASDAQ: GOSS

Gossamer Bio to Present at Cantor Global Healthcare Conference

· Issued by Gossamer Bio, Inc. via Business Wire

Summary by 6ix AI

Gossamer Bio, Inc., a clinical-stage drug developer working on seralutinib for two forms of high blood pressure in the lungs, will present at the Cantor Global Healthcare Conference, held September 9-11, 2026, in NYC, NY. Its presentation is set for September 9 at 10:55 AM ET.

Key details

  • The format is a presentation plus one-on-one meetings, and a webcast will be available.
  • Seralutinib is being developed for pulmonary arterial hypertension (PAH, high blood pressure in the arteries of the lungs) and pulmonary hypertension associated with interstitial lung disease (PH-ILD, lung high blood pressure linked to scarring lung diseases).

6ix AI wrote this summary from the release below and checked it against the release.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the Cantor Global Healthcare Conference to take place on September 9-11, 2026.

Cantor Global Healthcare Conference

Date / Time: September 9th, at 10:55 AM ET
Format: Presentation & 1x1’s
Location: NYC, NY
Webcast Link: Here

About Gossamer Bio

Gossamer Bio is a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension.

View original source (Business Wire)Gossamer Bio, Inc. on 6ix

Story so far

Earlier from Gossamer Bio

Later from Gossamer Bio

All Gossamer Bio news releases